Comparative Pharmacology
Head-to-head clinical analysis: IMURAN versus ZORTRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMURAN versus ZORTRESS.
IMURAN vs ZORTRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imuran (azathioprine) is a purine antimetabolite that inhibits DNA synthesis by interfering with purine metabolism. It is converted in vivo to 6-mercaptopurine (6-MP), which is further metabolized to thioinosinic acid and thioguanine nucleotides. These metabolites inhibit de novo purine synthesis and incorporation of purines into nucleic acids, thereby suppressing T-cell proliferation and antibody production.
Inhibits mammalian target of rapamycin (mTOR) by binding to FKBP-12, blocking cell cycle progression from G1 to S phase, thereby suppressing cytokine-driven T-cell proliferation.
Initially 3-5 mg/kg/day orally once daily; maintenance dose 1-3 mg/kg/day orally once daily. IV dose equivalent to oral.
1.5 mg orally twice daily, administered with cyclosporine and corticosteroids.
None Documented
None Documented
Azathioprine: 0.16–0.75 h; 6-mercaptopurine: 1.5–4.7 h (terminal). Extended up to 5 h in renal impairment. Context: short half-life allows daily dosing; clinical effect persists due to active metabolites.
Terminal elimination half-life is approximately 10-15 hours in renal transplant patients. In de novo liver transplant patients, half-life is ~13 hours. The effective half-life supports twice-daily dosing.
Primarily renal excretion of inactive metabolites; 50% as 6-thiouric acid and other metabolites; <2% unchanged. Minor biliary/fecal elimination (<10% total).
Primarily fecal (~78%) with <2.5% excreted unchanged in urine. Small amount via biliary elimination.
Category C
Category C
Immunosuppressant
Immunosuppressant